In vivo uterine local gene delivery system using TAT-displaying bionanocapsules.

BACKGROUND: The uterus is an organ that is directly accessible via the transvaginal route, whereas the drug delivery system and the gene delivery system (GDS) for the uterus are very limited, even in animal models. In the present study, we optimized a bionanocapsule (BNC) comprising a hepatitis B virus envelope L-protein particle, for which a structurally similar particle has been used as an immunogen of a conventional HB vaccine worldwide for more than 30 years, as a local uterine GDS using a mouse model. METHODS: To display various antibodies for re-targeting to different cells other than hepatic cells, the pre-S1 region of BNC was replaced with a tandem form of the protein A-derived immunoglobulin G Fc-interacting region (Z domain, ZZ-BNC). To induce strong cell adhesion after local administration into the uterine cavity, ZZ-BNC was modified with a transactivator of transcription (TAT) peptide. RESULTS: Gene transfer using TAT-modified ZZ-BNC is approximately 5000- or 18-fold more efficient than the introduction of the same dose of naked DNAs or the use of the cationic liposomes, respectively. TAT-modified ZZ-BNC was rapidly eliminated from the uterus and had no effect on the pregnancy rate, litter size or fetal growth. CONCLUSIONS: TAT-modified ZZ-BNC could be a useful GDS for uterine endometrial therapy via local uterine injection.

A case report of a 19-week gravid patient with a dehisced abdominal wound and treated with V.A.C. ATS(®) Therapy System.

Negative pressure wound therapy (NPWT) is an effective treatment for various non-healing wounds, and V.A.C.(®) Therapy was the first-approved NPWT device by the Japanese government in 2009. We report the case of a 19-week pregnant patient where V.A.C.(®) Therapy was applied to her dehisced laparotomy wound with satisfactory results. The patient was a 30-year-old female who was referred to our hospital from her previous doctor because of the presence of an ovarian cyst on the left ovary. The patient presented at 14 weeks into her pregnancy, and surgery was considered because of no reduction in the size of the cyst. An oophorocystectomy was performed, and then the surgical incision was re-opened at postoperative day (POD) 10 due to a surgical site infection. V.A.C.(®) Therapy was initiated on POD 26 (20 weeks of pregnancy) and continued for 28 days. After 28 days of V.A.C.(®) Therapy (POD 54), the wound was sutured for complete closure. The foetus did not experience any adverse affects from the surgery and, subsequently, normal vaginal delivery was achieved. This case is the first report of the use of V.A.C.(®) Therapy over a dehisced abdominal wound on a pregnant patient in our country.

Reaction of an oxaruthenacycle with DMAD. Stoichiometric transformations of 2,6-xylenol to allylic phenols and benzopyrans via sp(3) C-H bond cleavage reaction.

Insertion of a dimethyl acetylenedicarboxylate (DMAD) into the Ru-C bond in a cycloruthenated complex Ru[OC(6)H(3)(2-CH(2))(6-Me)-kappa(2)O,C](PMe(3))(4) () has been achieved to give a seven-membered oxaruthenacycle Ru[OC(6)H(3){2-CH(2)C(CO(2)Me)[double bond, length as m-dash]C(CO(2)Me)}(6-Me)-kappa(2)O,C](PMe(3))(3) () in 47% yield. The molecular structure of by X-ray analysis shows an agostic interaction between the ruthenium and one of the benzylic methylene protons. Complex shows fluxional behaviour in solution and the variable temperature NMR studies suggest this fluxionality to be responsible for the turnstile rotation of three PMe(3) ligands and the rotation of the alpha-methoxycarbonyl group. Heating of a toluene solution of at 100 degrees C for 2 h results in the 1,3-H shift reaction in to give a kappa(1)O,eta(3)-C,C',C'' allylic complex Ru[OC(6)H(3){2-CHC(CO(2)Me)CH(CO(2)Me)}(6-Me)-kappa(1)O,eta(3)C,C',C''](PMe(3))(3) () (80-90%), whose molecular structure is revealed by X-ray analysis. Acidolyses of and give 2-[(Z)-2',3'-bis(methoxycarbonyl)allyl]-6-methylphenol () (88%) and 2-[(Z)-2',3'-bis(methoxycarbonyl)propenyl]-6-methylphenol () (47%), respectively, and iodolyses of and produce 2,3-bis(methoxycarbonyl)-8-methyl-4H-benzopyran () (24%) and 2,3-bis(methoxycarbonyl)-8-methyl-2H-benzopyran () (48%), respectively.